Rodrigo Fernandes da Silva

Rodrigo Fernandes da Silva

Auto-generated profile, based on publicly available information

Rodrigo Fernandes da Silva

School of Medicine Sciences, University of Campinas, Rua Tessália Vieira de Camargo-126, Campinas CEP 13083-887, SP, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
WDWilliam K. Decker
William K. Decker
RSRodrigo F. da Silva
Rodrigo F. da Silva
MSMayra H. Sanabria
Mayra H. Sanabria
LALaura S. Angelo
Laura S. Angelo
FGFernando Guimarães
Fernando Guimarães
SPSilke Paust
Silke Paust
At the turn of the last century, the emerging field of medical oncology chose a cytotoxic ap-proach to cancer therapy over an immune-centered approach at a time when evidence in support of either paradigm did not yet exist. Today, nearly 120 years of data have established that a) even the best cytotoxic regimens only infrequently cure late-stage malignancy and b) strategies, which supplement and augment existing antitumor immune responses offer the greatest opportunities to potentiate durable remission in cancer. Despite widespread acceptance of these paradigms today, the ability of the immune system to recognize and fight cancer was a highly controversial topic for much of the 20th century. Why this modern paradigmatic mainstay should have been both du-bious and controversial for such an extended period is a topic of considerable interest that merits candid discussion. Herein we review the literature to identify and describe the watershed events that ultimately led to the acceptance of immunotherapy as a viable regimen for the treatment of neoplastic malignancy. In addition to noting important clinical discoveries, we also focus on research milestones and the development of critical model systems in rodents and dogs including the advanced modeling techniques that allowed development of patient-derived xenografts. Together, their use will further our understanding of cancer biology and anti-tumor immunology, allow for a speedier assessment of the efficacy and safety of novel approaches, and ultimately provide a faster bench to beside transition.

6 July 2021 in Cells
Verified
Journal Article
Open access
PDF file
CTCláudia Rodrigues Tonetti
Cláudia Rodrigues Tonetti
CACaroline Araujo
Caroline Araujo
AYAdriana Yoshida
Adriana Yoshida
RSRodrigo Fernandes da Silva
Rodrigo Fernandes da Silva
PAPaulo César Martins Alves
Paulo César Martins Alves
FGFernando Guimarães
Fernando Guimarães
Ovarian cancer is the most lethal gynecological malignancy, with serous histotype as the most prevalent epithelial ovarian cancer (EOC). Peritoneal ascites is a frequent comorbidity in advanced EOC. EOC-associated ascites provide a reliable sampling source for studying lymphocytes directly from tumor environment. Herein, we carried out flow cytometry-based analysis to readdress issues on NK and T lymphocyte subsets in women with advanced EOC, additionally evaluating phenotypic modulation of their intracellular pathways involved in interleukin (IL)-2 and IL-15 signaling. Results depicted ascites as an inflammatory and immunosuppressive environment, presenting significantly (p < 0.0001) higher amounts of IL-6 and IL-10 than in the patients’ blood, as well as significantly (p < 0.05) increased expression of checkpoint inhibitory receptors (programmed death protein-1, PD-1) and ectonucleotidase (CD39) on T lymphocytes. However, NK lymphocytes from EOC-associated ascites showed higher (p < 0.05) pS6 phosphorylation compared with NK from blood. Additionally, in vitro treatment of lymphocytes with IL-2 or IL-15 elicited significantly (p < 0.001) phosphorylation of the STAT5 protein in NK, CD3 and CD8 lymphocytes, both from blood and ascites. EOC-associated ascites had a significantly (p < 0.0001) higher proportion of NK CD56bright lymphocytes than blood, which, in addition, were more responsive (p < 0.05) to stimulation by IL-2 than CD56dim NK. EOC-associated ascites allow studies on lymphocyte phenotype modulation in the tumor environment, where inflammatory profile contrasts with the presence of immunosuppressive elements and development of cellular self-regulating mechanisms.

Verified
Journal Article
Open access
PDF file
RSRodrigo Fernandes Da Silva
Rodrigo Fernandes Da Silva
AYAdriana Yoshida
Adriana Yoshida
DCDaniela Maira Maira Cardozo
Daniela Maira Maira Cardozo
RJRodrigo Jales
Rodrigo Jales
SPSilke Paust
Silke Paust
FGFernando Guimarães
Fernando Guimarães
Peritoneal ascites are a distinguishable feature of patients with advanced epithelial ovarian cancer (EOC). The presence of different lymphocyte subsets has been reported in EOC-associated ascites, which also can or not contain malignant cells. The goal of this study was to analyze the functional characteristics of natural killer (NK) cells from EOC-associated ascites in terms of their expression of activating receptors and ascites’ contents of lymphocyte subtypes, cytokine profile and presence of EOC cells. NK cell function was evaluated by the expression of the degranulation marker CD107a in resting and interleukin (IL)-2 stimulated NK cells from ascites and blood. Degranulation of NK cells from EOC cell-free ascites was significantly (p < 0.05) higher than all the other groups, either in their resting state or after IL-2 stimulation, suggesting a previous local stimulation. In contrast, treatment with IL-2 had no effect on NK cells from ascites with EOC cells. The amount of regulatory T cells was significantly higher in ascites with EOC cells compared to EOC cell-free ascites. Ascites with EOC cells also had higher levels of tumor necrosis factor (TNF)-α, suggesting inflammation related to the malignancy. In conclusion, the functional performance of NK cells was distinct between EOC cell-free ascites and ascites with EOC cells. The impairment of NK cell response to IL-2 in ascites with EOC cells was consistent with an immunosuppressive tumor microenvironment.

1 October 2016 in Human Immunology
Verified
Journal Article
Closed access
DCDaniela Maira Cardozo
Daniela Maira Cardozo
AMAmanda Vansan Marangon
Amanda Vansan Marangon
RSRodrigo Fernandes da Silva
Rodrigo Fernandes da Silva
FAFrancisco José Penteado Aranha
Francisco José Penteado Aranha
Jeane Eliete Laguila VisentainerJeane Eliete Laguila Visentainer
Jeane Eliete Laguila Visentainer
FGFernando Guimarães
Fernando Guimarães

1 August 2014 in Human Immunology
Verified
Journal Article
Closed access
RSRodrigo Fernandes da Silva
Rodrigo Fernandes da Silva
CPCarlos Alberto Petta
Carlos Alberto Petta
SDSophie Françoise Mauricette Derchain
Sophie Françoise Mauricette Derchain
EAEvren Alici
Evren Alici
FGFernando Guimarães
Fernando Guimarães

13 November 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RSRodrigo Fernandes da Silva
Rodrigo Fernandes da Silva
DCDaniela Maira Maira Cardozo
Daniela Maira Maira Cardozo
GRGisele Olinto Libanio Rodrigues
Gisele Olinto Libanio Rodrigues
CACaroline Araujo
Caroline Araujo
Natacha MigitaNatacha Migita
Natacha Migita
FGFernando Guimarães
Fernando Guimarães
The spontaneous immortalization of primary malignant cells is frequently assigned to their genetic instability during in vitro culturing. In this study, the new epithelial ovarian cancer cell line CAISMOV24 was described and compared with its original low-grade serous ovarian carcinoma. The in vitro culture was established with cells isolated from ascites of a 60-year-old female patient with recurrent ovarian cancer. The CAISMOV24 line was assessed for cell growth, production of soluble biomarkers, expression of surface molecules and screened for typical mutations found in serous ovarian carcinoma. Additionally, comparative genomic hybridization was employed to compare genomic alterations between the CAISMOV24 cell line and its primary malignant cells. CAISMOV24 has been in continuous culture for more than 30 months and more than 100 in vitro passages. The cell surface molecules EpCAM, PVR and CD73 are overexpressed on CAISMOV24 cells compared to the primary malignant cells. CAISMOV24 continues to produce CA125 and HE4 in vitro. Although the cell line had developed alongside the accumulation of genomic alterations (28 CNV in primary cells and 37 CNV in CAISMOV24), most of them were related to CNVs already present in primary malignant cells. CAISMOV24 cell line harbored KRAS mutation with wild type TP53, therefore it is characterized as low-grade serous carcinoma. Our results corroborate with the idea that genomic alterations, depicted by CNVs, can be used for subtyping epithelial ovarian carcinomas. Additionally, CAISMOV24 cell line was characterized as a low-grade serous ovarian carcinoma, which still resembles its primary malignant cells.